enkephalin, leucine has been researched along with Disease Exacerbation in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Abujrais, S; Bergquist, J; Burman, J; Constantinescu, R; Kneider, M; Landtblom, AM; Niemela, V; Nyholm, D; Paucar, M; Shevchenko, G; Sundblom, J; Svenningsson, P | 1 |
| Chen, Q; Guo, WH; Li, JB; Liu, J; Liu, WJ; Liu, XL; Yang, CQ; Yin, DC; Zhang, CY; Zhang, G; Zhang, SL; Zhao, G | 1 |
| Aramin, H; Arbit, B; Clopton, P; Lee, EL; Maisel, AS; Marston, N; Shah, K | 1 |
| Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
| Chesselet, MF; Li, H; Li, XJ; Menalled, LB; Olivieri, M; Sison, JD; Wu, Y; Zeitlin, S | 1 |
| Bezard, E; Brotchie, JM; Gross, CE | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Meissner, W | 1 |
| Maidment, NT; Rocha, L | 1 |
| Caron, MG; Chavkin, C; Czyzyk, TA; Lefkowitz, RJ; McLaughlin, JP; Petraschka, M; Pintar, JE; Terman, GW; Westenbroek, RE; Xu, M | 1 |
| Ariano, MA; Buchanan, TM; Collier, TJ; Elsworth, JD; Grissell, AE; Littlejohn, FC; Steece-Collier, K | 1 |
| Benraiss, A; Chmielnicki, E; Cho, SR; Economides, A; Goldman, SA; Samdani, A | 1 |
| Beaufour, C; Braz, J; Cesselin, F; Coutaux, A; Epstein, AL; Hamon, M; Pohl, M | 1 |
| Boissonade, FM; Rodd, HD | 1 |
1 review(s) available for enkephalin, leucine and Disease Exacerbation
| Article | Year |
|---|---|
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.
Topics: Adaptation, Physiological; Animals; Basal Ganglia; Disease Progression; Dopamine; Enkephalins; Globus Pallidus; Humans; Models, Neurological; Parkinson Disease; Receptors, Dopamine D2; Substantia Nigra | 2003 |
12 other study(ies) available for enkephalin, leucine and Disease Exacerbation
| Article | Year |
|---|---|
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease.
Topics: Biomarkers; Disease Progression; Enkephalins; Humans; Huntington Disease; Neurons; Protein Precursors; Proteomics | 2021 |
miR-506-loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple-negative breast cancer aggressiveness.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Female; Gelatin; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Mice; MicroRNAs; Nanospheres; Protein Precursors; Proto-Oncogene Proteins c-fos; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Prognostic Usefulness of Proenkephalin in Stable Ambulatory Patients With Heart Failure.
Topics: Aged; Biomarkers; California; Cause of Death; Disease Progression; Echocardiography; Enkephalins; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Outpatients; Prognosis; Prospective Studies; Protein Precursors; Risk Assessment; Risk Factors; Survival Rate; Time Factors | 2016 |
Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Brain; CD11b Antigen; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Disease Progression; Dopamine; Electrochemistry; Enkephalins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Locomotion; Male; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Olfactory Bulb; Parkinsonian Disorders; Time Factors; Tyrosine 3-Monooxygenase | 2009 |
Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
Topics: Animals; Behavior, Animal; Cell Count; Cell Nucleus; Corpus Striatum; Disease Models, Animal; Disease Progression; Enkephalins; Female; Grooming; Huntingtin Protein; Huntington Disease; Inclusion Bodies; Macromolecular Substances; Male; Mice; Mice, Mutant Strains; Motor Activity; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Organ Specificity; Phenotype; Receptors, Opioid, mu; RNA, Messenger; Trinucleotide Repeat Expansion | 2002 |
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Disease Progression; Electron Transport Complex IV; Enkephalins; Gene Expression Regulation; In Situ Hybridization; Male; Mice; Mice, Inbred C57BL; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tachykinins | 2003 |
Opioid peptide release in the rat hippocampus after kainic acid-induced status epilepticus.
Topics: Animals; Disease Models, Animal; Disease Progression; Down-Regulation; Dynorphins; Enkephalins; Epilepsy, Temporal Lobe; Excitatory Amino Acid Agonists; Glutamic Acid; Hippocampus; Immunohistochemistry; Kainic Acid; Male; Opioid Peptides; Rats; Rats, Wistar; Reaction Time; Status Epilepticus | 2003 |
Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.
Topics: Animals; Astrocytes; Disease Models, Animal; Disease Progression; Drug Tolerance; Dynorphins; Enkephalins; G-Protein-Coupled Receptor Kinase 3; Hyperalgesia; Lumbosacral Region; Mice; Mice, Inbred C57BL; Mice, Knockout; Narcotic Antagonists; Narcotics; Neuralgia; Neurons; Protein Precursors; Protein Serine-Threonine Kinases; Receptors, Opioid; Receptors, Opioid, kappa; Sciatic Neuropathy; Spinal Cord | 2004 |
Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Efferent Pathways; Enkephalins; Enzyme Activation; Male; Mitochondrial Proteins; Nerve Degeneration; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease.
Topics: Adenoviridae; Animals; Brain-Derived Neurotrophic Factor; Carrier Proteins; Disease Models, Animal; Disease Progression; Enkephalins; Globus Pallidus; Huntington Disease; Mice; Mice, Transgenic; Mitosis; Neostriatum; Neurons; Regeneration; Substance P; Tubulin | 2007 |
Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons.
Topics: Animals; Arthritis; Arthritis, Experimental; Disease Models, Animal; Disease Progression; Enkephalins; Freund's Adjuvant; Ganglia, Spinal; Genes, Reporter; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; Hindlimb; Hyperalgesia; Male; Neurons, Afferent; Pain Measurement; Protein Precursors; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Terminal Repeat Sequences; Treatment Outcome | 2001 |
Comparative immunohistochemical analysis of the peptidergic innervation of human primary and permanent tooth pulp.
Topics: Analysis of Variance; Calcitonin Gene-Related Peptide; Child; Dental Caries; Dental Pulp; Dentition, Permanent; Disease Progression; Enkephalins; Fluorescent Antibody Technique, Indirect; Galanin; Humans; Molar; Neurogenic Inflammation; Neuropeptide Y; Neuropeptides; Somatostatin; Statistics, Nonparametric; Substance P; Tooth, Deciduous; Vasoactive Intestinal Peptide | 2002 |